8-K: Matinas BioPharma Announces Second Quarter 2024 Financial Results and Provides Business Update

Matinas BioPharma reported its second quarter 2024 financial results, highlighted by a non-binding term sheet for global licensing of MAT2203 and progress in its compassionate use program.

Summary

• Matinas BioPharma announced its financial results for the second quarter of 2024, showing no revenue for the quarter, consistent with the same period in 2023.
• Total costs and expenses for the second quarter of 2024 were $5.8 million, a decrease from $6.2 million in the second quarter of 2023.
• The net loss for the second quarter of 2024 was $5.7 million, or $0.02 per share, compared to a net loss of $6.1 million, or $0.03 per share, in the second quarter of 2023.
• For the six months ended June 30, 2024, the company reported no revenue, compared to $1.1 million in the same period of 2023.
• Total costs and expenses for the first six months of 2024 were $11.7 million, compared to $12.8 million for the first six months of 2023.
• The net loss for the first six months of 2024 was $11.5 million, or $0.05 per share, compared to a net loss of $11.6 million, or $0.05 per share, in the first six months of 2023.
• As of June 30, 2024, the company had $14.3 million in cash, cash equivalents, and marketable securities, up from $13.8 million at the end of 2023.
• In April 2024, Matinas BioPharma raised $10.0 million through a registered direct offering.
• The company signed a non-binding term sheet for global licensing rights to MAT2203, an oral formulation of amphotericin B.
• 31 patients have enrolled in the MAT2203 Compassionate/Expanded Use Access Program, with 6 additional patients under evaluation.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the progress in the MAT2203 program and the non-binding term sheet, but tempered by the lack of revenue and ongoing losses. The potential of the LNC platform is promising, but still in early stages.

Positives

• The company has secured a non-binding term sheet for global licensing of MAT2203, indicating potential future revenue streams.
• The Compassionate/Expanded Use Access Program for MAT2203 has shown positive results, with a significant number of patients experiencing complete responses or improvement.
• The company's cash position has improved to $14.3 million, providing financial stability.
• The net loss for the second quarter of 2024 decreased compared to the same period in 2023.
• The LNC platform shows promise in delivering various therapeutic agents, including oncology drugs and oligonucleotides.

Negatives

• The company reported no revenue for the second quarter of 2024 and the first six months of 2024.
• The company continues to operate at a loss, with a net loss of $5.7 million for the second quarter and $11.5 million for the first six months of 2024.
• Some in vivo studies of orally administered LNC-formulated small oligonucleotides have been less consistent in showing therapeutic efficacy.
• Studies of LNC-docetaxel and LNC-miriplatin showed significant weight loss in addition to tumor inhibition.

Risks

• The company's ability to continue as a going concern is dependent on securing additional capital.
• The success of the MAT2203 program is contingent on securing a partnership agreement.
• Clinical trials are subject to inherent uncertainties and may not yield positive results.
• The company faces competition in the biopharmaceutical industry.
• Regulatory approvals for the company's products are not guaranteed.
• The company's intellectual property may not be adequately protected.

Future Outlook

The company expects to provide additional guidance following the consummation of a MAT2203 partnership. They are also evaluating the next steps for their LNC platform technology to maximize shareholder return.

Management Comments

• We continue to engage in constructive partnership dialogues for MAT2203 and are pleased to announce that we have signed a non-binding term sheet for global licensing rights to this oral formulation of the potent, yet toxic antifungal amphotericin B, said Jerome D. Jabbour, Chief Executive Officer of Matinas.
• We are experiencing a dramatic increase in requests by physicians seeking access for their patients who have limited or no treatment options, which we attribute to the consistently positive clinical impact of MAT2203 in successfully treating a variety of deadly invasive fungal infections.
• Recent studies have increased our understanding of the potential for our LNC platform in delivering both small oligonucleotides and small molecule oncology drugs, including LNC cellular uptake and cargo delivery.

Industry Context

The announcement highlights Matinas BioPharma's progress in developing novel therapies for invasive fungal infections, a significant unmet medical need. The company's LNC platform technology positions it to potentially compete with existing drug delivery methods in the biopharmaceutical industry.

Comparison to Industry Standards

• Matinas BioPharma's focus on oral delivery of amphotericin B addresses a key limitation of existing intravenous formulations, which are associated with significant toxicity, similar to other companies working on novel drug delivery systems.
• The positive results from the Compassionate/Expanded Use Access Program for MAT2203 are encouraging, but further data from the planned Phase 3 trial will be needed to confirm its efficacy and safety, similar to other companies in the clinical trial phase.
• The company's financial results are typical for a clinical-stage biopharmaceutical company, with no revenue and ongoing losses, similar to other companies in the development phase.
• The non-binding term sheet for global licensing of MAT2203 is a positive step, but the company will need to secure a binding agreement to realize its potential, similar to other companies seeking partnerships.

Stakeholder Impact

• Shareholders may be encouraged by the progress of the MAT2203 program and the potential for future revenue.
• Employees may be impacted by the company's financial performance and future strategic decisions.
• Patients with invasive fungal infections may benefit from the development of MAT2203.
• Potential partners may be interested in the licensing opportunity for MAT2203.

Next Steps

• The company will continue to engage in partnership discussions for MAT2203.
• Preparations are ongoing to enable the initiation of the ORALTO Phase 3 registration trial of MAT2203.
• The company will evaluate the next steps for its LNC platform technology.
• Additional studies are evaluating several strategies to potentially improve the therapeutic index of docetaxel.

Key Dates

Keywords

MAT2203, LNC platform, amphotericin B, invasive aspergillosis, fungal infections, oncology, oligonucleotides, clinical trials, biopharmaceutical, drug delivery